@marionyger.bsky.social
Reposted
ASSET-IT phase 3 trial: Guidelines recommend intravenous thrombolysis within 4.5 hours after onset of acute ischemic stroke, but vascular reocclusion may occur. Adjunct treatment with tirofiban might improve outcomes. Research findings are summarized in a new Quick Take video. nej.md/4pAB0iQ
September 29, 2025 at 7:14 PM
ASSET-IT phase 3 trial: Guidelines recommend intravenous thrombolysis within 4.5 hours after onset of acute ischemic stroke, but vascular reocclusion may occur. Adjunct treatment with tirofiban might improve outcomes. Research findings are summarized in a new Quick Take video. nej.md/4pAB0iQ
Reposted
Large-vessel vasculitis is defined as diseases that cause inflammation in large blood vessels.
A new Seminar provides a comprehensive review, with a focus on recent advances, therapeutic approaches, and areas for further research.
Read now: tinyurl.com/ynsfkev5
A new Seminar provides a comprehensive review, with a focus on recent advances, therapeutic approaches, and areas for further research.
Read now: tinyurl.com/ynsfkev5
September 18, 2025 at 2:37 PM
Large-vessel vasculitis is defined as diseases that cause inflammation in large blood vessels.
A new Seminar provides a comprehensive review, with a focus on recent advances, therapeutic approaches, and areas for further research.
Read now: tinyurl.com/ynsfkev5
A new Seminar provides a comprehensive review, with a focus on recent advances, therapeutic approaches, and areas for further research.
Read now: tinyurl.com/ynsfkev5
Reposted
Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo
August 30, 2025 at 7:01 PM
Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo
Reposted
ICYMI: New online! Spreading depolarization as a therapeutic target in migraine
Spreading depolarization as a therapeutic target in migraine
Nature Reviews Neurology, Published online: 14 August 2025; doi:10.1038/s41582-025-01128-0Spreading depolarization is widely accepted as the cause of migraine aura, but its relationship with migraine headache is less clear. In this Review, Harriott and Ayata review the evidence that links spreading depolarization with the headache phase of migraine with aura, and consider the potential of therapeutic targeting of spreading depolarization in migraine.
bit.ly
August 15, 2025 at 5:03 PM
ICYMI: New online! Spreading depolarization as a therapeutic target in migraine
Reposted
ICYMI: Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) tinyurl.com/8hbp7nt4
July 9, 2025 at 2:45 PM
ICYMI: Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST) tinyurl.com/8hbp7nt4
Reposted
Check out our July issue featuring blood pressure lowering after acute intracerebral haemorrhage, the potential of the α-synuclein seed amplification assay, cognitive decline in Down syndrome and more: tinyurl.com/3pvve45t
June 25, 2025 at 9:02 AM
Check out our July issue featuring blood pressure lowering after acute intracerebral haemorrhage, the potential of the α-synuclein seed amplification assay, cognitive decline in Down syndrome and more: tinyurl.com/3pvve45t
Reposted
Extending the treatment window for intravenous thrombolysis beyond 4.5 hours may benefit patients with posterior circulation ischemic stroke. Research findings are summarized in a new Quick Take video. nej.md/4lfwHrd
#MedSky #NeuroSky
#MedSky #NeuroSky
April 6, 2025 at 7:01 PM
Extending the treatment window for intravenous thrombolysis beyond 4.5 hours may benefit patients with posterior circulation ischemic stroke. Research findings are summarized in a new Quick Take video. nej.md/4lfwHrd
#MedSky #NeuroSky
#MedSky #NeuroSky
Reposted
In patients with posterior circulation stroke for whom thrombectomy was not planned, alteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days than standard treatment. Full EXPECTS trial results: nej.md/3QTnMxG
#MedSky #NeuroSky
#MedSky #NeuroSky
April 2, 2025 at 10:08 PM
In patients with posterior circulation stroke for whom thrombectomy was not planned, alteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days than standard treatment. Full EXPECTS trial results: nej.md/3QTnMxG
#MedSky #NeuroSky
#MedSky #NeuroSky
Reposted
Presented at #ACC25:
Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results: nej.md/4kWjJyn
#MedSky @accintouch.bsky.social
Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results: nej.md/4kWjJyn
#MedSky @accintouch.bsky.social
March 30, 2025 at 6:35 PM
Presented at #ACC25:
Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results: nej.md/4kWjJyn
#MedSky @accintouch.bsky.social
Lepodisiran, an extended-duration, small interfering RNA, reduced lipoprotein(a) concentrations in participants with elevated levels. Full ALPACA trial results: nej.md/4kWjJyn
#MedSky @accintouch.bsky.social
Reposted
New in the March 27, 2025, issue of NEJM:
Blood-Pressure Control in Patients with Diabetes (BPROAD trial) nej.md/4eyDckd
Inebilizumab for Treatment of IgG4-Related Disease (MITIGATE phase 3 trial) nej.md/4euxr6Y
#MedSky
Blood-Pressure Control in Patients with Diabetes (BPROAD trial) nej.md/4eyDckd
Inebilizumab for Treatment of IgG4-Related Disease (MITIGATE phase 3 trial) nej.md/4euxr6Y
#MedSky
March 27, 2025 at 1:04 PM
New in the March 27, 2025, issue of NEJM:
Blood-Pressure Control in Patients with Diabetes (BPROAD trial) nej.md/4eyDckd
Inebilizumab for Treatment of IgG4-Related Disease (MITIGATE phase 3 trial) nej.md/4euxr6Y
#MedSky
Blood-Pressure Control in Patients with Diabetes (BPROAD trial) nej.md/4eyDckd
Inebilizumab for Treatment of IgG4-Related Disease (MITIGATE phase 3 trial) nej.md/4euxr6Y
#MedSky
Reposted
What is the impact of microplastics on human health? The latest episode of Beyond Journal Club, a collaboration between @coreimpodcast.bsky.social and NEJM Group, takes a deep dive into the APAChE study on microplastics and cardiovascular disease. 🎧 Listen here: nej.md/4igpJQy
#MedSky
#MedSky
March 18, 2025 at 7:30 PM
What is the impact of microplastics on human health? The latest episode of Beyond Journal Club, a collaboration between @coreimpodcast.bsky.social and NEJM Group, takes a deep dive into the APAChE study on microplastics and cardiovascular disease. 🎧 Listen here: nej.md/4igpJQy
#MedSky
#MedSky